Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04725812 · ClinicalTrials.gov registry record · Phase 2
Complement Regulation to Undo Systemic Harm in Preeclampsia
A Phase 2 study, sponsored by Cedars-Sinai Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04725812 is a Phase 2 study that was terminated before completion, run by Cedars-Sinai Medical Center. The registered enrollment target is 2 participants.
The verdict
NCT04725812, a Phase 2 study, was terminated before completion, sponsored by Cedars-Sinai Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a Phase II, single arm, open-label study to determine if treatment with eculizumab prolongs pregnancy compared to historical controls in women with preeclampsia between 23-30 weeks gestation.
Interventions
- DRUG Eculizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-09-13 |
| Est. Completion | 2021-12-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04725812
The ClinicalTrials.gov registry entry for NCT04725812 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Eculizumab is the first listed.
NCT04725812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04725812 about?
NCT04725812 is a clinical study titled "Complement Regulation to Undo Systemic Harm in Preeclampsia". This is a Phase II, single arm, open-label study to determine if treatment with eculizumab prolongs pregnancy compared to historical controls in women with preeclampsia between 23-30 weeks gestation.
What is the current status of trial NCT04725812?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2021-09-13. Estimated completion is 2021-12-07.
What interventions are being tested in trial NCT04725812?
The interventions under investigation include: Eculizumab (DRUG).
Who is sponsoring clinical trial NCT04725812?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.